Your browser doesn't support javascript.
loading
Using seconds-resolved pharmacokinetic datasets to assess pharmacokinetic models encompassing time-varying physiology.
McDonough, Matthew H; Stocker, Sophie L; Kippin, Tod E; Meiring, Wendy; Plaxco, Kevin W.
Affiliation
  • McDonough MH; Department of Statistics and Applied Probability, University of California Santa Barbara, Santa Barbara, California, USA.
  • Stocker SL; School of Pharmacy, Faculty of Medicine and Health, University of Sydney, New South Wales, Sydney, Australia.
  • Kippin TE; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
  • Meiring W; Department of Psychological and Brain Sciences, University of California Santa Barbara, Santa Barbara, California, USA.
  • Plaxco KW; The Neuroscience Research Institute and Department of Molecular Cellular and Developmental Biology, University of California Santa Barbara, Santa Barbara, California, USA.
Br J Clin Pharmacol ; 89(9): 2798-2812, 2023 09.
Article in En | MEDLINE | ID: mdl-37186478
ABSTRACT

AIM:

Pharmacokinetics have historically been assessed using drug concentration data obtained via blood draws and bench-top analysis. The cumbersome nature of these typically constrains studies to at most a dozen concentration measurements per dosing event. This, in turn, limits our statistical power in the detection of hours-scale, time-varying physiological processes. Given the recent advent of in vivo electrochemical aptamer-based (EAB) sensors, however, we can now obtain hundreds of concentration measurements per administration. Our aim in this paper was to assess the ability of these time-dense datasets to describe time-varying pharmacokinetic models with good statistical significance.

METHODS:

We used seconds-resolved measurements of plasma tobramycin concentrations in rats to statistically compare traditional one- and two-compartmental pharmacokinetic models to new models in which the proportional relationship between a drug's plasma concentration and its elimination rate varies in response to changing kidney function.

RESULTS:

We found that a modified one-compartment model in which the proportionality between the plasma concentration of tobramycin and its elimination rate falls reciprocally with time either meets or is preferred over the standard two-compartment pharmacokinetic model for half of the datasets characterized. When we reduced the impact of the drug's rapid distribution phase on the model, this one-compartment, time-varying model was statistically preferred over the standard one-compartment model for 80% of our datasets.

CONCLUSIONS:

Our results highlight both the impact that simple physiological changes (such as varying kidney function) can have on drug pharmacokinetics and the ability of high-time resolution EAB sensor measurements to identify such impacts.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tobramycin / Models, Biological Type of study: Prognostic_studies Limits: Animals Language: En Journal: Br J Clin Pharmacol Year: 2023 Document type: Article Affiliation country: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tobramycin / Models, Biological Type of study: Prognostic_studies Limits: Animals Language: En Journal: Br J Clin Pharmacol Year: 2023 Document type: Article Affiliation country: Estados Unidos